The bidirectional interation between pancreatic cancer and diabetes

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Li, Junhui ^a   Cao, Gang ^a   Ma, Qingyong ^a   Liu, Han ^a   Li, Wei ^a   Han, Liang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Bidirectional interation; Diabetes; Pancreatic cancer; Review

Indexed keywords

CYTOKINE; INSULIN; METFORMIN;

CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; EARLY DIAGNOSIS; EVIDENCE BASED PRACTICE; GENOTYPE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; METASTASIS; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; REVIEW; TUMOR VOLUME;

EID: 84865301780     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-171     Document Type: Review

References (95)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
2. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, Pan L, Anderson RN, Fulton JE, Kohler BA, Jemal A, Ward E, Plescia M, Ries LA, Edwards BK. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012, 118:2338-2366. 10.1002/cncr.27514, 22460733.
3. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2 - an independent risk factor for cancer?. Exp Clin Endocrinol Diabetes 2010, 118:4-8. 10.1055/s-0029-1243193, 20127570.
4. Huxley R, Ansary-Moghaddam A, Berrington De-González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005, 92:2076-2083. 10.1038/sj.bjc.6602619, 2361795, 15886696.
5. Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011, 22:189-197. 10.1007/s10552-010-9686-3, 21104117.
6. Ogunleye AA, Ogston SA, Morris AD, Evans JM. A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 2009, 101:1199-1201. 10.1038/sj.bjc.6605240, 2768085, 19690547.
7. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg?. Pancreas 2011, 40:339-351. 10.1097/MPA.0b013e318209e05d, 21412116.
8. Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011, 54:2263-2271. 10.1007/s00125-011-2242-1, 21748485.
9. Perrin MC, Terry MB, Kleinhaus K, Deutsch L, Yanetz R, Tiram E, Calderon R, Friedlander Y, Paltiel O, Harlap S. Gestational diabetes as a risk factor for pancreatic cancer: a prospective cohort study. BMC Med 2007, 5:25-31. 10.1186/1741-7015-5-25, 2042496, 17705823.
10. Tseng CH. New-onset diabetes with a history of dyslipidemia predicts pancreatic cancer. Pancreas 2012, Jun. [Epub ahead of print].
11. Ogawa Y, Tanaka M, Inoue K, Yamaguchi K, Chijiiwa K, Mizumoto K, Tsutsu N, Nakamura Y. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 2002, 94:2344-2349. 10.1002/cncr.10493, 12015758.
12. Hong SG, Jung SJ, Joo MK, Lee BJ, Yeon JE, Park JJ, Byun KS, Bak YT. Prevalence of pancreatic cancer in diabetics and clinical characteristics of diabetes-associated with pancreatic cancer-comparison between diabetes with and without pancreatic cancer. Korean J Gastroenterol 2009, 54:167-173. 10.4166/kjg.2009.54.3.167, 19844153.
13. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005, 129:504-511. 2377196, 16083707.
14. Jamal MM, Yoon EJ, Vega KJ, Hashemzadeh M, Chang KJ. Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J Gastroenterol 2009, 15:5274-5278. 10.3748/wjg.15.5274, 2776853, 19908334.
15. Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 2007, 96:507-509. 10.1038/sj.bjc.6603571, 2360024, 17224924.
16. Saruç M, Karaarslan M, Rasa K, Saygili O, Ince U, Baysal C, Pour PM, Cakmakçi M, TözÃ1-Aprn N. Pancreatic cancer and glucose metabolism. Turk J Gastroenterol 2009, 20:257-260.
17. Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. Mol Cancer 2003, 2:4. 10.1186/1476-4598-2-4, 149418, 12556242.
18. Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev 2006, 15:1458-1463. 10.1158/1055-9965.EPI-06-0188, 16896032.
19. Aggarwal G, Rabe KG, Petersen GM, Chari ST. New-onset diabetes in pancreatic cancer: a study in the primary care setting. Pancreatology 2012, 12:156-161.
20. Permert J, Adrian TE, Jacobsson P, Jorfelt L, Fruin AB, Larsson J. Is profound peripheral insulin resistance in patients with PaC caused by a tumor-associated factor?. Am J Surg 1993, 165:61-67. 10.1016/S0002-9610(05)80405-2, 8380314.
21. Kuang TT, da Jin Y, Wang DS, Xu XF, Ni XL, Wu WC, Lou WH. Clinical epidemiological analysis of the relationship between pancreatic cancer and diabetes mellitus: data from a single institution in China. J Dig Dis 2009, 10:26-29. 10.1111/j.1751-2980.2008.00359.x, 19236544.
22. Matsubayashi H, Maeda A, Kanemoto H, Uesaka K, Yamazaki K, Hironaka S, Miyagi Y, Ikehara H, Ono H, Klein A, Goggins M. Risk factors of familial pancreatic cancer in Japan: current smoking and recent onset of diabetes. Pancreas 2011, 40:974-978. 10.1097/MPA.0b013e3182156e1b, 21487321.
23. Bartsch DK, Kress R, Sina-Frey M, Grutzmann R, Gerdes B, Pilarsky C, Heise JW, Schulte KM, Colombo-Benkmann M, Schleicher C, Witzigmann H, Pridohl O, Ghadimi M, Horstmann OV, Berndorff W, Jochimsen L, Schmidt J, Eisold S, Estevez-Schwarz L, Hahn SA, Schulmann K, Bock W, Gress T, Zugel N, Breitschaft K, Prenzel K, Messmann H, Endlicher E, Schneider M, Ziegler A, et al. Prevalence of familial pancreatic cancer in Germany. Int J Cancer 2004, 110:902-906. 10.1002/ijc.20210, 15170674.
24. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003, 124:1292-1299. 10.1016/S0016-5085(03)00272-5, 12730869.
25. Uni W, Shelly N, Richard Z. Pancreatic adenocarcinoma (PA) and diabetes mellitus (DM). Gastroenterology 2010, 138:S-553.
26. Butler AE, Galasso R, Matveyenko A, Rizza RA, Dry S, Butler PC. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 2010, 53:21-26. 10.1007/s00125-009-1556-8, 2789928, 19844672.
27. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM. Prevention of PaC induction in hamsters by metformin. Gastroenterology 2001, 120:1263-1270. 10.1053/gast.2001.23258, 11266389.
28. Liu J, Knezetic JA, Strömmer L, Permert J, Larsson J, Adrian TE. The intracellular mechanism of insulin resistance in pancreatic cancer patients. J Clin End Met 2000, 85:1232-1238.
29. Permert J, Herrington M, Kazakoff K, Pour PM, Adrian TE. Early changes in islet hormone secretion in the hamster pancreatic cancer model. Teratog Carcinog Mutagen 2001, 21:59-67. 10.1002/1520-6866(2001)21:1<59::AID-TCM6>3.0.CO;2-V, 11135321.
30. Krechler T, Jachymova M, Pavlikova M, Vecka M, Zeman M, Krska Z, Svestka T, Zak A. Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: a pilot study. Neoplasma 2009, 56:26-32. 10.4149/neo_2009_01_26, 19152242.
31. Pantalone D, Ragionieri I, Nesi G. Improved survival in small pancreatic cancer. Dig Surg 2001, 18:41-46. 10.1159/000050095, 11244258.
32. Chu CK, Mazo AE, Goodman M, Egnatashvili V, Sarmiento JM, Staley CA, Galloway JR, Adsay NV, Jacobs S, Kooby DA. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol 2010, 17:502-513. 10.1245/s10434-009-0789-6, 19885697.
33. Fisher WE, McCullough PJ, Ray MB, Rogers DH, Bell RH. Diabetes enhances growth of pancreatic carcinoma cells. Surgery 1988, 104:431-436.
34. Dong X, Li Y, Chang P, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism gene variants modulate the risk of pancreatic cancer. Cancer Prev Res (Phila) 2011, 4:758-766.
35. Fryzek JP, Garabrant DH, Schenk M, Kinnard M, Greenson JK, Sarkar FH. The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations. Int J Gastrointest Cancer 2006, 37:139-145.
36. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995, 55:2007-2011.
37. Suzuki H, Li Y, Dong X, Hassan MM, Abbruzzese JL, Li D. Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:3467-3473. 10.1158/1055-9965.EPI-08-0514, 2600618, 19064563.
38. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology 2010, 139:464-473. 473.e1-3, 10.1053/j.gastro.2010.04.042, 2910789, 20416304.
39. Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G, Giunco S, Valerio A, Navaglia F, Zambon CF, Falda A, Pedrazzoli S, Plebani M. Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause?. Clin Chim Acta 2006, 372:120-128. 10.1016/j.cca.2006.03.027, 16678810.
40. Basso D, Greco E, Padoan A, Fogar P, Scorzeto M, Fadi E, Bozzato D, Moz S, Navaglia F, Zambon CF, Seraglia R, De Carlo E, Valerio A, Reggiani C, Pedrazzoli S, Plebani M. Altered intracellular calcium fluxes in pancreatic cancer induced diabetes mellitus: relevance of the S100A8 N-terminal peptide (NT-S100A8). J Cell Physiol 2011, 226:456-468. 10.1002/jcp.22355, 20717964.
41. Zhou L, Zhang R, Wang L, Shen S, Okamoto H, Sugawara A, Xia L, Wang X, Noguchi N, Yoshikawa T, Uruno A, Yao W, Yuan Y. Upregulation of REG Ialpha accelerates tumor progression in pancreatic cancer with diabetes. Int J Cancer 2010, 127:1795-1803. 10.1002/ijc.25188, 20099282.
42. Tingstedt B, Johansson P, Andersson B, Andersson R. Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response. Scand J Gastroenterol 2007, 42:754-759. 10.1080/00365520601058452, 17505998.
43. Fogar P, Basso D, Pasquali C, Piva MG, Brigato L, De Paoli M, Galeotti F, Corsini A, Plebani M. Portal but not peripheral serum levels of interleukin 6 could interfere with glucose metabolism in patients with pancreatic cancer. Clin Chim Acta 1998, 277:181-189. 10.1016/S0009-8981(98)00125-9, 9853701.
44. Basso D, Millino C, Greco E, Romualdi C, Fogar P, Valerio A, Bellin M, Zambon CF, Navaglia F, Dussini N, Avogaro A, Pedrazzoli S, Lanfranchi G, Plebani M. Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut 2004, 53:1159-1166. 10.1136/gut.2003.024471, 1774152, 15247186.
45. Takada M, Koizumi T, Toyama H, Suzuki Y, Kuroda Y. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology 2001, 48:1577-1578.
46. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 2004, 51:928-930.
47. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820. 10.1038/414813a, 11742414.
48. Busik JV, Hootman SR, Greenidge CA, Henry DN. Glucosespecific regulation of aldose reductase in capan-1 human pancreatic duct cells in vitro. J Clin Invest 1997, 100:1685-1692. 10.1172/JCI119693, 508351, 9312166.
49. Li W, Ma Q, Li J, Guo K, Liu H, Han L, Ma G. Hyperglycemia enhances the invasive and migratory activity of pancreatic cancer cells via hydrogen peroxide. Oncol Rep 2011, 25:1279-1287.
50. Sindhu RK, Koo JR, Roberts CK, Vaziri ND. Dysregulation of hepatic superoxide dismutase, catalase and glutathione peroxidase in diabetes: response to insulin and antioxidant therapies. Clin Exp Hypert 2004, 26:43-53.
51. Cullen JJ, Weydert C, Hinkhouse MM, Ritchie J, Domann FE, Spitz D, Oberley LW. The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. Cancer Res 2003, 63:1297-1303.
52. Cullen JJ, Mitros FA, Oberley LW. Expression of antioxidant enzymes in diseases of the human pancreas: another link between chronic pancreatitis and pancreatic cancer. Pancreas 2003, 26:23-27. 10.1097/00006676-200301000-00005, 12499913.
53. Suzuki K, Islam KN, Kaneto H, Ookawara T, Taniguchi N. The contribution of fructose and nitric oxide to oxidative stress in hamster islet tumor (HIT) cells through the inactivation of glutathione peroxidase. Electrophoresis 2000, 21:285-288. 10.1002/(SICI)1522-2683(20000101)21:2<285::AID-ELPS285>3.0.CO;2-5, 10675001.
54. Veit C, Genze F, Menke A, Hoeffert S, Gress TM, Gierschik P, Giehl K. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res 2004, 64:5291-5300. 10.1158/0008-5472.CAN-04-1112, 15289335.
55. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001, 12:361-373. 10.1016/S1359-6101(01)00012-0, 11544105.
56. Liu H, Ma QY, Li JH. High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells. Mol Cell Biochem 2011, 347:95-101. 10.1007/s11010-010-0617-0, 20960036.
57. Han L, Ma Q, Li J, Liu H, Li W, Ma G, Xu Q, Zhou S, Wu E. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One 2011, 6:e27074. 10.1371/journal.pone.0027074, 3210779, 22087246.
58. Li JH, Ma QY. Hyperglycemia promotes the perineural invasion in pancreatic cancer. Med Hypotheses 2008, 71:386-389. 10.1016/j.mehy.2008.05.001, 18571873.
59. Li J, Ma Q, Liu H, Guo K, Li F, Li W, Han L, Wang F, Wu E. Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia. PLoS One 2011, 6:e17385. 10.1371/journal.pone.0017385, 3046240, 21386984.
60. Pannala R, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM, Chari ST. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 2009, 104:2318-2325. 10.1038/ajg.2009.253, 2779576, 19513024.
61. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008, 134:95-101. 10.1053/j.gastro.2007.10.040, 2271041, 18061176.
62. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009, 10:88-95. 10.1016/S1470-2045(08)70337-1, 2795483, 19111249.
63. Centers for Disease Control and Prevention National Diabetes Fact Sheet. 2007, Centers for Disease Control and Prevention.
64. Park HY, Song SY, Cho HC, Lee KH, Lee KT, Lee JK. Clinical characteristics of pancreatic cancer-associated new onset diabetes. Gastroenterology 2010, 138:1391.
65. Gullo L, Pezzilli R, Morselli-Labate AM, Italian Pancreatic Cancer Study Group Diabetes and the risk of pancreatic cancer. N Engl J Med 1994, 331:81-84. 10.1056/NEJM199407143310203, 8208269, Italian Pancreatic Cancer Study Group.
66. Hart PA, Kamada P, Rabe KG, Srinivasan S, Basu A, Aggarwal G, Chari ST. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas 2011, 40:768-772. 10.1097/MPA.0b013e318220816a, 3118443, 21654538.
67. Chen HF, Chen P, Li CY. Risk of malignant neoplasm of the pancreas in relation to diabetes: a population-based study in Taiwan. Diabetes Care 2011, 34:1177-1179. 10.2337/dc10-2006, 3114480, 21398527.
68. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008, 134:981-987. 10.1053/j.gastro.2008.01.039, 2323514, 18395079.
69. Lin MV, Bishop G, Benito-Herrero M. Diabetic ketoacidosis in type 2 diabetics: a novel presentation of pancreatic adenocarcinoma. J Gen Intern Med 2010, 25:369-373. 10.1007/s11606-009-1237-9, 2842543, 20119682.
70. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993, 80:1047-1050. 10.1002/bjs.1800800841, 8402064.
71. Chari ST, Zapiach M, Yadav D, Rizza RA. Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology 2005, 5:229-233. 10.1159/000085276, 15855820.
72. Leighton B, Cooper GJ. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 1988, 335:632-635. 10.1038/335632a0, 3050530.
73. Saruc M, Iki K, Pour PM. Morphometric studies in human pancreatic cancer argues against the etiological role of type 2 diabetes in pancreatic cancer. Histol Histopathol 2010, 25:423-432.
74. Katsumichi I, Pour PM. Diabetes mellitus in pancreatic cancer: is it a causal relationship?. Am J Surg 2007, 194:S71-S75. 10.1016/j.amjsurg.2007.05.024, 17903450.
75. Kolb A, Rieder S, Born D, Giese NA, Giese T, Rudofsky G, Werner J, BÃ1-Aprchler MW, Friess H, Esposito I, Kleeff J. Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus. Cancer Biol Ther 2009, 8:1527-1533.
76. Aggarwal G, Klee G, Fernandez-Zapico ME, Klee EW, Smyrk TC, Andrade M, Petersen GM, Chari ST. Adrenomedullin: a biomarker of pancreatic cancer-associated diabetes?. Gastroenterology 2010, 138:S-551.
77. Sharaf RN, Butte AJ, Montgomery KD, Pai R, Dudley JT, Pasricha PJ. Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes. BMC Gastroenterol 2011, 11:5. 10.1186/1471-230X-11-5, 3037918, 21251264.
78. Huang H, Dong X, Kang MX, Xu B, Chen Y, Zhang B, Chen J, Xie QP, Wu YL. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J Gastroenterol 2010, 105:1661-1669. 10.1038/ajg.2010.32, 20571492.
79. Ding X, Flatt PR, Permert J, Adrian TE. Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology 1998, 114:130-138. 10.1016/S0016-5085(98)70641-9, 9428227.
80. Guo Q, Kang M, Zhang B, Chen Y, Dong X, Wu Y. Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes. J Cancer Res Clin Oncol 2010, 136:1627-1631. 10.1007/s00432-010-0820-0, 20174821.
81. Sookwong P, Nakagawa K, Fujita I, Shoji N, Miyazawa T. Amadori-glycated phosphatidylethanolamine, a potential marker for hyperglycemia, in streptozotocin-induced diabetic rats. Lipids 2011, 46:943-952. 10.1007/s11745-011-3588-3, 21732214.
82. Eitsuka T, Nakagawa K, Ono Y, Tatewaki N, Nishida H, Kurata T, Shoji N, Miyazawa T. Amadori-glycated phosphatidylethanolamine up-regulates telomerase activity in PANC-1 human pancreatic carcinoma cells. FEBS Lett 2012, 586:2542-2547. 10.1016/j.febslet.2012.06.027, 22750441.
83. Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L, Fadi E, Zambon CF, Bozzato D, Moz S, Seraglia R, Pedrazzoli S, Plebani M. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin Chem Lab Med 2009, 47:713-723.
84. Fukamachi K, Tanaka H, Hagiwara Y, Ohara H, Joh T, Iigo M, Alexander DB, Xu J, Long N, Takigahira M, Yanagihara K, Hino O, Saito I, Tsuda H. An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas. Biochem Biophys Res Commun 2009, 390:636-641. 10.1016/j.bbrc.2009.10.019, 19818733.
85. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 2007, 102:2157-2163. 10.1111/j.1572-0241.2007.01480.x, 17897335.
86. Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, Chuang LM, Lai MS. Associated with insulin glargine among adult type 2 diabetes patients - a nationwide cohort study. PLoS One 2011, 6:e21368. 10.1371/journal.pone.0021368, 3124499, 21738645.
87. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 2011, 15:825-836. 10.1111/j.1582-4934.2010.01083.x, 2930937, 20455996.
88. Chagpar RB, Martin RC, Ahmad SA, Kim HJ, Rupp C, Weber S, Ebelhar A, Gilbert J, Brinkman A, Winslow E, Cho CS, Kooby D, Chu CK, Staley CA, McMasters KM, Scoggins CR. Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer. J Gastrointest Surg 2011, 15:551-557. 10.1007/s11605-011-1448-3, 21327533.
89. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011, 11:20. 10.1186/1471-2407-11-20, 3031263, 21241523.
90. Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 2009, 115:86-96. 10.1080/13813450902878054, 19485704.
91. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777. 10.1007/s00125-009-1440-6, 19572116.
92. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006, 66:10269-10273. 10.1158/0008-5472.CAN-06-1500, 17062558.
93. Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010, 16:2505-2511. 10.1158/1078-0432.CCR-09-2229, 2862089, 20388847.
94. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009, 69:6539-6545. 10.1158/0008-5472.CAN-09-0418, 2753241, 19679549.
95. Nath SD, Habib SL, Abboud HE. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005, 293:2210-2211.